Loading…

Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection

Considerable concerns relating to the duration of protective immunity against severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) exist, with evidence of antibody titers declining rapidly after infection and reports of reinfection. Here, we monitor the antibody responses against SARS-CoV-2...

Full description

Saved in:
Bibliographic Details
Published in:Cell reports. Medicine 2021-04, Vol.2 (4), p.100228-100228, Article 100228
Main Authors: Abayasingam, Arunasingam, Balachandran, Harikrishnan, Agapiou, David, Hammoud, Mohamed, Rodrigo, Chaturaka, Keoshkerian, Elizabeth, Li, Hui, Brasher, Nicholas A., Christ, Daniel, Rouet, Romain, Burnet, Deborah, Grubor-Bauk, Branka, Rawlinson, William, Turville, Stuart, Aggarwal, Anupriya, Stella, Alberto Ospina, Fichter, Christina, Brilot, Fabienne, Mina, Michael, Post, Jeffrey J., Hudson, Bernard, Gilroy, Nicky, Dwyer, Dominic, Sasson, Sarah C., Tea, Fiona, Pilli, Deepti, Kelleher, Anthony, Tedla, Nicodemus, Lloyd, Andrew R., Martinello, Marianne, Bull, Rowena A.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c587t-c19ea1bd65128a1b1c01670ec2f669f8aec479d46ba11b5669c172dae934120e3
cites cdi_FETCH-LOGICAL-c587t-c19ea1bd65128a1b1c01670ec2f669f8aec479d46ba11b5669c172dae934120e3
container_end_page 100228
container_issue 4
container_start_page 100228
container_title Cell reports. Medicine
container_volume 2
creator Abayasingam, Arunasingam
Balachandran, Harikrishnan
Agapiou, David
Hammoud, Mohamed
Rodrigo, Chaturaka
Keoshkerian, Elizabeth
Li, Hui
Brasher, Nicholas A.
Christ, Daniel
Rouet, Romain
Burnet, Deborah
Grubor-Bauk, Branka
Rawlinson, William
Turville, Stuart
Aggarwal, Anupriya
Stella, Alberto Ospina
Fichter, Christina
Brilot, Fabienne
Mina, Michael
Post, Jeffrey J.
Hudson, Bernard
Gilroy, Nicky
Dwyer, Dominic
Sasson, Sarah C.
Tea, Fiona
Pilli, Deepti
Kelleher, Anthony
Tedla, Nicodemus
Lloyd, Andrew R.
Martinello, Marianne
Bull, Rowena A.
description Considerable concerns relating to the duration of protective immunity against severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) exist, with evidence of antibody titers declining rapidly after infection and reports of reinfection. Here, we monitor the antibody responses against SARS-CoV-2 receptor-binding domain (RBD) for up to 6 months after infection. While antibody titers are maintained, ∼13% of the cohort’s neutralizing responses return to background. However, encouragingly, in a selected subset of 13 participants, 12 have detectable RBD-specific memory B cells and these generally are increasing out to 6 months. Furthermore, we are able to generate monoclonal antibodies with SARS-CoV-2 neutralizing capacity from these memory B cells. Overall, our study suggests that the loss of neutralizing antibodies in plasma may be countered by the maintenance of neutralizing capacity in the memory B cell repertoire. [Display omitted] Decay of antibody binding to RBD and spike antigen after 6 months11 of 81 (13.6%) participants revert to background neutralizing levelsDespite declining antibody titers, robust memory B cell populations are observedMemory B cells retain potent neutralizing capacity Abayasingam et al. report that despite the declining anti-RBD antibody titers and neutralizing capacity of antibodies in the serum at 6 months, the memory B cells still contain RBD-specific reactivity that have the capacity to generate antibodies that can neutralize SARS-CoV-2 in vitro.
doi_str_mv 10.1016/j.xcrm.2021.100228
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_f87c028de7894e22a0d1a4e95ff87962</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2666379121000446</els_id><doaj_id>oai_doaj_org_article_f87c028de7894e22a0d1a4e95ff87962</doaj_id><sourcerecordid>2503669947</sourcerecordid><originalsourceid>FETCH-LOGICAL-c587t-c19ea1bd65128a1b1c01670ec2f669f8aec479d46ba11b5669c172dae934120e3</originalsourceid><addsrcrecordid>eNp9UU1v1DAQtRCIVqV_gAPyEQllsZ3EHxJCapevSishtcDVcuzJ4lViL3a2avn1OKRU7YWTZ968eeOZh9BLSlaUUP52t7qxaVwxwmgBCGPyCTpmnPOqFoo-fRAfodOcd6RwWkplTZ6jo7oWjRRSHiPYxLCtJkgj3kPKPk8QLODY48vzD2_wCGNMt_gcWxiGjEstOh-2OMBhSmbwv-fEhMl3BYeMfcBXZ5dX1Tr-qFjJerCTj-EFetabIcPp3XuCvn_6-G39pdp8_XyxPttUtpViqixVYGjneEuZLAG1ZVNBwLKec9VLA7YRyjW8M5R2bcEsFcwZUHVDGYH6BF0sui6and4nP5p0q6Px-i8Q01abNHk7gO6lsIRJB0KqBhgzxFHTgGr7UlGcFa33i9b-0I3gLIR540eijyvB_9TbeK2FalvFVBF4fSeQ4q8D5EmPPs93NAHiIWvWkrqsoBpRqGyh2hRzTtDfj6FEz3brnZ7t1rPderG7NL16-MH7ln_mFsK7hQDl5Nceks7Wz_Y6n4ov5Sb-f_p_AAMku6c</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2503669947</pqid></control><display><type>article</type><title>Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection</title><source>ScienceDirect</source><source>PubMed Central</source><creator>Abayasingam, Arunasingam ; Balachandran, Harikrishnan ; Agapiou, David ; Hammoud, Mohamed ; Rodrigo, Chaturaka ; Keoshkerian, Elizabeth ; Li, Hui ; Brasher, Nicholas A. ; Christ, Daniel ; Rouet, Romain ; Burnet, Deborah ; Grubor-Bauk, Branka ; Rawlinson, William ; Turville, Stuart ; Aggarwal, Anupriya ; Stella, Alberto Ospina ; Fichter, Christina ; Brilot, Fabienne ; Mina, Michael ; Post, Jeffrey J. ; Hudson, Bernard ; Gilroy, Nicky ; Dwyer, Dominic ; Sasson, Sarah C. ; Tea, Fiona ; Pilli, Deepti ; Kelleher, Anthony ; Tedla, Nicodemus ; Lloyd, Andrew R. ; Martinello, Marianne ; Bull, Rowena A.</creator><creatorcontrib>Abayasingam, Arunasingam ; Balachandran, Harikrishnan ; Agapiou, David ; Hammoud, Mohamed ; Rodrigo, Chaturaka ; Keoshkerian, Elizabeth ; Li, Hui ; Brasher, Nicholas A. ; Christ, Daniel ; Rouet, Romain ; Burnet, Deborah ; Grubor-Bauk, Branka ; Rawlinson, William ; Turville, Stuart ; Aggarwal, Anupriya ; Stella, Alberto Ospina ; Fichter, Christina ; Brilot, Fabienne ; Mina, Michael ; Post, Jeffrey J. ; Hudson, Bernard ; Gilroy, Nicky ; Dwyer, Dominic ; Sasson, Sarah C. ; Tea, Fiona ; Pilli, Deepti ; Kelleher, Anthony ; Tedla, Nicodemus ; Lloyd, Andrew R. ; Martinello, Marianne ; Bull, Rowena A. ; on Behalf of the COSIN Study Group ; COSIN Study Group</creatorcontrib><description>Considerable concerns relating to the duration of protective immunity against severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) exist, with evidence of antibody titers declining rapidly after infection and reports of reinfection. Here, we monitor the antibody responses against SARS-CoV-2 receptor-binding domain (RBD) for up to 6 months after infection. While antibody titers are maintained, ∼13% of the cohort’s neutralizing responses return to background. However, encouragingly, in a selected subset of 13 participants, 12 have detectable RBD-specific memory B cells and these generally are increasing out to 6 months. Furthermore, we are able to generate monoclonal antibodies with SARS-CoV-2 neutralizing capacity from these memory B cells. Overall, our study suggests that the loss of neutralizing antibodies in plasma may be countered by the maintenance of neutralizing capacity in the memory B cell repertoire. [Display omitted] Decay of antibody binding to RBD and spike antigen after 6 months11 of 81 (13.6%) participants revert to background neutralizing levelsDespite declining antibody titers, robust memory B cell populations are observedMemory B cells retain potent neutralizing capacity Abayasingam et al. report that despite the declining anti-RBD antibody titers and neutralizing capacity of antibodies in the serum at 6 months, the memory B cells still contain RBD-specific reactivity that have the capacity to generate antibodies that can neutralize SARS-CoV-2 in vitro.</description><identifier>ISSN: 2666-3791</identifier><identifier>EISSN: 2666-3791</identifier><identifier>DOI: 10.1016/j.xcrm.2021.100228</identifier><identifier>PMID: 33748788</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antibodies, Neutralizing - blood ; Antibodies, Neutralizing - immunology ; Asymptomatic Diseases ; COSIN ; COVID ; COVID-19 - immunology ; COVID-19 - pathology ; COVID-19 - virology ; Female ; functional MBCs ; Humans ; Limit of Detection ; longitudinal tracking ; Male ; memory B cells ; Memory B Cells - metabolism ; Middle Aged ; Neutralization Tests ; neutralizing antibodies ; Protein Domains - immunology ; RBD ; RBD tetramer ; SARS-CoV-2 ; SARS-CoV-2 - isolation &amp; purification ; SARS-CoV-2 - metabolism ; SARS-CoV-2 pseudovirus ; Severity of Illness Index ; Spike Glycoprotein, Coronavirus - chemistry ; Spike Glycoprotein, Coronavirus - immunology ; Spike Glycoprotein, Coronavirus - metabolism ; Time Factors ; Young Adult</subject><ispartof>Cell reports. Medicine, 2021-04, Vol.2 (4), p.100228-100228, Article 100228</ispartof><rights>2021 The Author(s)</rights><rights>2021 The Author(s).</rights><rights>2021 The Author(s) 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c587t-c19ea1bd65128a1b1c01670ec2f669f8aec479d46ba11b5669c172dae934120e3</citedby><cites>FETCH-LOGICAL-c587t-c19ea1bd65128a1b1c01670ec2f669f8aec479d46ba11b5669c172dae934120e3</cites><orcidid>0000-0002-0009-3337 ; 0000-0002-5329-9072 ; 0000-0003-0365-087X ; 0000-0003-3913-3751 ; 0000-0002-7163-2844 ; 0000-0002-7952-7969 ; 0000-0002-4642-105X ; 0000-0003-2189-9177 ; 0000-0001-9336-0555 ; 0000-0002-7951-8763</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955929/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S2666379121000446$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,3549,27924,27925,45780,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33748788$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abayasingam, Arunasingam</creatorcontrib><creatorcontrib>Balachandran, Harikrishnan</creatorcontrib><creatorcontrib>Agapiou, David</creatorcontrib><creatorcontrib>Hammoud, Mohamed</creatorcontrib><creatorcontrib>Rodrigo, Chaturaka</creatorcontrib><creatorcontrib>Keoshkerian, Elizabeth</creatorcontrib><creatorcontrib>Li, Hui</creatorcontrib><creatorcontrib>Brasher, Nicholas A.</creatorcontrib><creatorcontrib>Christ, Daniel</creatorcontrib><creatorcontrib>Rouet, Romain</creatorcontrib><creatorcontrib>Burnet, Deborah</creatorcontrib><creatorcontrib>Grubor-Bauk, Branka</creatorcontrib><creatorcontrib>Rawlinson, William</creatorcontrib><creatorcontrib>Turville, Stuart</creatorcontrib><creatorcontrib>Aggarwal, Anupriya</creatorcontrib><creatorcontrib>Stella, Alberto Ospina</creatorcontrib><creatorcontrib>Fichter, Christina</creatorcontrib><creatorcontrib>Brilot, Fabienne</creatorcontrib><creatorcontrib>Mina, Michael</creatorcontrib><creatorcontrib>Post, Jeffrey J.</creatorcontrib><creatorcontrib>Hudson, Bernard</creatorcontrib><creatorcontrib>Gilroy, Nicky</creatorcontrib><creatorcontrib>Dwyer, Dominic</creatorcontrib><creatorcontrib>Sasson, Sarah C.</creatorcontrib><creatorcontrib>Tea, Fiona</creatorcontrib><creatorcontrib>Pilli, Deepti</creatorcontrib><creatorcontrib>Kelleher, Anthony</creatorcontrib><creatorcontrib>Tedla, Nicodemus</creatorcontrib><creatorcontrib>Lloyd, Andrew R.</creatorcontrib><creatorcontrib>Martinello, Marianne</creatorcontrib><creatorcontrib>Bull, Rowena A.</creatorcontrib><creatorcontrib>on Behalf of the COSIN Study Group</creatorcontrib><creatorcontrib>COSIN Study Group</creatorcontrib><title>Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection</title><title>Cell reports. Medicine</title><addtitle>Cell Rep Med</addtitle><description>Considerable concerns relating to the duration of protective immunity against severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) exist, with evidence of antibody titers declining rapidly after infection and reports of reinfection. Here, we monitor the antibody responses against SARS-CoV-2 receptor-binding domain (RBD) for up to 6 months after infection. While antibody titers are maintained, ∼13% of the cohort’s neutralizing responses return to background. However, encouragingly, in a selected subset of 13 participants, 12 have detectable RBD-specific memory B cells and these generally are increasing out to 6 months. Furthermore, we are able to generate monoclonal antibodies with SARS-CoV-2 neutralizing capacity from these memory B cells. Overall, our study suggests that the loss of neutralizing antibodies in plasma may be countered by the maintenance of neutralizing capacity in the memory B cell repertoire. [Display omitted] Decay of antibody binding to RBD and spike antigen after 6 months11 of 81 (13.6%) participants revert to background neutralizing levelsDespite declining antibody titers, robust memory B cell populations are observedMemory B cells retain potent neutralizing capacity Abayasingam et al. report that despite the declining anti-RBD antibody titers and neutralizing capacity of antibodies in the serum at 6 months, the memory B cells still contain RBD-specific reactivity that have the capacity to generate antibodies that can neutralize SARS-CoV-2 in vitro.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Neutralizing - blood</subject><subject>Antibodies, Neutralizing - immunology</subject><subject>Asymptomatic Diseases</subject><subject>COSIN</subject><subject>COVID</subject><subject>COVID-19 - immunology</subject><subject>COVID-19 - pathology</subject><subject>COVID-19 - virology</subject><subject>Female</subject><subject>functional MBCs</subject><subject>Humans</subject><subject>Limit of Detection</subject><subject>longitudinal tracking</subject><subject>Male</subject><subject>memory B cells</subject><subject>Memory B Cells - metabolism</subject><subject>Middle Aged</subject><subject>Neutralization Tests</subject><subject>neutralizing antibodies</subject><subject>Protein Domains - immunology</subject><subject>RBD</subject><subject>RBD tetramer</subject><subject>SARS-CoV-2</subject><subject>SARS-CoV-2 - isolation &amp; purification</subject><subject>SARS-CoV-2 - metabolism</subject><subject>SARS-CoV-2 pseudovirus</subject><subject>Severity of Illness Index</subject><subject>Spike Glycoprotein, Coronavirus - chemistry</subject><subject>Spike Glycoprotein, Coronavirus - immunology</subject><subject>Spike Glycoprotein, Coronavirus - metabolism</subject><subject>Time Factors</subject><subject>Young Adult</subject><issn>2666-3791</issn><issn>2666-3791</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp9UU1v1DAQtRCIVqV_gAPyEQllsZ3EHxJCapevSishtcDVcuzJ4lViL3a2avn1OKRU7YWTZ968eeOZh9BLSlaUUP52t7qxaVwxwmgBCGPyCTpmnPOqFoo-fRAfodOcd6RwWkplTZ6jo7oWjRRSHiPYxLCtJkgj3kPKPk8QLODY48vzD2_wCGNMt_gcWxiGjEstOh-2OMBhSmbwv-fEhMl3BYeMfcBXZ5dX1Tr-qFjJerCTj-EFetabIcPp3XuCvn_6-G39pdp8_XyxPttUtpViqixVYGjneEuZLAG1ZVNBwLKec9VLA7YRyjW8M5R2bcEsFcwZUHVDGYH6BF0sui6and4nP5p0q6Px-i8Q01abNHk7gO6lsIRJB0KqBhgzxFHTgGr7UlGcFa33i9b-0I3gLIR540eijyvB_9TbeK2FalvFVBF4fSeQ4q8D5EmPPs93NAHiIWvWkrqsoBpRqGyh2hRzTtDfj6FEz3brnZ7t1rPderG7NL16-MH7ln_mFsK7hQDl5Nceks7Wz_Y6n4ov5Sb-f_p_AAMku6c</recordid><startdate>20210420</startdate><enddate>20210420</enddate><creator>Abayasingam, Arunasingam</creator><creator>Balachandran, Harikrishnan</creator><creator>Agapiou, David</creator><creator>Hammoud, Mohamed</creator><creator>Rodrigo, Chaturaka</creator><creator>Keoshkerian, Elizabeth</creator><creator>Li, Hui</creator><creator>Brasher, Nicholas A.</creator><creator>Christ, Daniel</creator><creator>Rouet, Romain</creator><creator>Burnet, Deborah</creator><creator>Grubor-Bauk, Branka</creator><creator>Rawlinson, William</creator><creator>Turville, Stuart</creator><creator>Aggarwal, Anupriya</creator><creator>Stella, Alberto Ospina</creator><creator>Fichter, Christina</creator><creator>Brilot, Fabienne</creator><creator>Mina, Michael</creator><creator>Post, Jeffrey J.</creator><creator>Hudson, Bernard</creator><creator>Gilroy, Nicky</creator><creator>Dwyer, Dominic</creator><creator>Sasson, Sarah C.</creator><creator>Tea, Fiona</creator><creator>Pilli, Deepti</creator><creator>Kelleher, Anthony</creator><creator>Tedla, Nicodemus</creator><creator>Lloyd, Andrew R.</creator><creator>Martinello, Marianne</creator><creator>Bull, Rowena A.</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-0009-3337</orcidid><orcidid>https://orcid.org/0000-0002-5329-9072</orcidid><orcidid>https://orcid.org/0000-0003-0365-087X</orcidid><orcidid>https://orcid.org/0000-0003-3913-3751</orcidid><orcidid>https://orcid.org/0000-0002-7163-2844</orcidid><orcidid>https://orcid.org/0000-0002-7952-7969</orcidid><orcidid>https://orcid.org/0000-0002-4642-105X</orcidid><orcidid>https://orcid.org/0000-0003-2189-9177</orcidid><orcidid>https://orcid.org/0000-0001-9336-0555</orcidid><orcidid>https://orcid.org/0000-0002-7951-8763</orcidid></search><sort><creationdate>20210420</creationdate><title>Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection</title><author>Abayasingam, Arunasingam ; Balachandran, Harikrishnan ; Agapiou, David ; Hammoud, Mohamed ; Rodrigo, Chaturaka ; Keoshkerian, Elizabeth ; Li, Hui ; Brasher, Nicholas A. ; Christ, Daniel ; Rouet, Romain ; Burnet, Deborah ; Grubor-Bauk, Branka ; Rawlinson, William ; Turville, Stuart ; Aggarwal, Anupriya ; Stella, Alberto Ospina ; Fichter, Christina ; Brilot, Fabienne ; Mina, Michael ; Post, Jeffrey J. ; Hudson, Bernard ; Gilroy, Nicky ; Dwyer, Dominic ; Sasson, Sarah C. ; Tea, Fiona ; Pilli, Deepti ; Kelleher, Anthony ; Tedla, Nicodemus ; Lloyd, Andrew R. ; Martinello, Marianne ; Bull, Rowena A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c587t-c19ea1bd65128a1b1c01670ec2f669f8aec479d46ba11b5669c172dae934120e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Neutralizing - blood</topic><topic>Antibodies, Neutralizing - immunology</topic><topic>Asymptomatic Diseases</topic><topic>COSIN</topic><topic>COVID</topic><topic>COVID-19 - immunology</topic><topic>COVID-19 - pathology</topic><topic>COVID-19 - virology</topic><topic>Female</topic><topic>functional MBCs</topic><topic>Humans</topic><topic>Limit of Detection</topic><topic>longitudinal tracking</topic><topic>Male</topic><topic>memory B cells</topic><topic>Memory B Cells - metabolism</topic><topic>Middle Aged</topic><topic>Neutralization Tests</topic><topic>neutralizing antibodies</topic><topic>Protein Domains - immunology</topic><topic>RBD</topic><topic>RBD tetramer</topic><topic>SARS-CoV-2</topic><topic>SARS-CoV-2 - isolation &amp; purification</topic><topic>SARS-CoV-2 - metabolism</topic><topic>SARS-CoV-2 pseudovirus</topic><topic>Severity of Illness Index</topic><topic>Spike Glycoprotein, Coronavirus - chemistry</topic><topic>Spike Glycoprotein, Coronavirus - immunology</topic><topic>Spike Glycoprotein, Coronavirus - metabolism</topic><topic>Time Factors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abayasingam, Arunasingam</creatorcontrib><creatorcontrib>Balachandran, Harikrishnan</creatorcontrib><creatorcontrib>Agapiou, David</creatorcontrib><creatorcontrib>Hammoud, Mohamed</creatorcontrib><creatorcontrib>Rodrigo, Chaturaka</creatorcontrib><creatorcontrib>Keoshkerian, Elizabeth</creatorcontrib><creatorcontrib>Li, Hui</creatorcontrib><creatorcontrib>Brasher, Nicholas A.</creatorcontrib><creatorcontrib>Christ, Daniel</creatorcontrib><creatorcontrib>Rouet, Romain</creatorcontrib><creatorcontrib>Burnet, Deborah</creatorcontrib><creatorcontrib>Grubor-Bauk, Branka</creatorcontrib><creatorcontrib>Rawlinson, William</creatorcontrib><creatorcontrib>Turville, Stuart</creatorcontrib><creatorcontrib>Aggarwal, Anupriya</creatorcontrib><creatorcontrib>Stella, Alberto Ospina</creatorcontrib><creatorcontrib>Fichter, Christina</creatorcontrib><creatorcontrib>Brilot, Fabienne</creatorcontrib><creatorcontrib>Mina, Michael</creatorcontrib><creatorcontrib>Post, Jeffrey J.</creatorcontrib><creatorcontrib>Hudson, Bernard</creatorcontrib><creatorcontrib>Gilroy, Nicky</creatorcontrib><creatorcontrib>Dwyer, Dominic</creatorcontrib><creatorcontrib>Sasson, Sarah C.</creatorcontrib><creatorcontrib>Tea, Fiona</creatorcontrib><creatorcontrib>Pilli, Deepti</creatorcontrib><creatorcontrib>Kelleher, Anthony</creatorcontrib><creatorcontrib>Tedla, Nicodemus</creatorcontrib><creatorcontrib>Lloyd, Andrew R.</creatorcontrib><creatorcontrib>Martinello, Marianne</creatorcontrib><creatorcontrib>Bull, Rowena A.</creatorcontrib><creatorcontrib>on Behalf of the COSIN Study Group</creatorcontrib><creatorcontrib>COSIN Study Group</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Cell reports. Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abayasingam, Arunasingam</au><au>Balachandran, Harikrishnan</au><au>Agapiou, David</au><au>Hammoud, Mohamed</au><au>Rodrigo, Chaturaka</au><au>Keoshkerian, Elizabeth</au><au>Li, Hui</au><au>Brasher, Nicholas A.</au><au>Christ, Daniel</au><au>Rouet, Romain</au><au>Burnet, Deborah</au><au>Grubor-Bauk, Branka</au><au>Rawlinson, William</au><au>Turville, Stuart</au><au>Aggarwal, Anupriya</au><au>Stella, Alberto Ospina</au><au>Fichter, Christina</au><au>Brilot, Fabienne</au><au>Mina, Michael</au><au>Post, Jeffrey J.</au><au>Hudson, Bernard</au><au>Gilroy, Nicky</au><au>Dwyer, Dominic</au><au>Sasson, Sarah C.</au><au>Tea, Fiona</au><au>Pilli, Deepti</au><au>Kelleher, Anthony</au><au>Tedla, Nicodemus</au><au>Lloyd, Andrew R.</au><au>Martinello, Marianne</au><au>Bull, Rowena A.</au><aucorp>on Behalf of the COSIN Study Group</aucorp><aucorp>COSIN Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection</atitle><jtitle>Cell reports. Medicine</jtitle><addtitle>Cell Rep Med</addtitle><date>2021-04-20</date><risdate>2021</risdate><volume>2</volume><issue>4</issue><spage>100228</spage><epage>100228</epage><pages>100228-100228</pages><artnum>100228</artnum><issn>2666-3791</issn><eissn>2666-3791</eissn><abstract>Considerable concerns relating to the duration of protective immunity against severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) exist, with evidence of antibody titers declining rapidly after infection and reports of reinfection. Here, we monitor the antibody responses against SARS-CoV-2 receptor-binding domain (RBD) for up to 6 months after infection. While antibody titers are maintained, ∼13% of the cohort’s neutralizing responses return to background. However, encouragingly, in a selected subset of 13 participants, 12 have detectable RBD-specific memory B cells and these generally are increasing out to 6 months. Furthermore, we are able to generate monoclonal antibodies with SARS-CoV-2 neutralizing capacity from these memory B cells. Overall, our study suggests that the loss of neutralizing antibodies in plasma may be countered by the maintenance of neutralizing capacity in the memory B cell repertoire. [Display omitted] Decay of antibody binding to RBD and spike antigen after 6 months11 of 81 (13.6%) participants revert to background neutralizing levelsDespite declining antibody titers, robust memory B cell populations are observedMemory B cells retain potent neutralizing capacity Abayasingam et al. report that despite the declining anti-RBD antibody titers and neutralizing capacity of antibodies in the serum at 6 months, the memory B cells still contain RBD-specific reactivity that have the capacity to generate antibodies that can neutralize SARS-CoV-2 in vitro.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>33748788</pmid><doi>10.1016/j.xcrm.2021.100228</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-0009-3337</orcidid><orcidid>https://orcid.org/0000-0002-5329-9072</orcidid><orcidid>https://orcid.org/0000-0003-0365-087X</orcidid><orcidid>https://orcid.org/0000-0003-3913-3751</orcidid><orcidid>https://orcid.org/0000-0002-7163-2844</orcidid><orcidid>https://orcid.org/0000-0002-7952-7969</orcidid><orcidid>https://orcid.org/0000-0002-4642-105X</orcidid><orcidid>https://orcid.org/0000-0003-2189-9177</orcidid><orcidid>https://orcid.org/0000-0001-9336-0555</orcidid><orcidid>https://orcid.org/0000-0002-7951-8763</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2666-3791
ispartof Cell reports. Medicine, 2021-04, Vol.2 (4), p.100228-100228, Article 100228
issn 2666-3791
2666-3791
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_f87c028de7894e22a0d1a4e95ff87962
source ScienceDirect; PubMed Central
subjects Adult
Aged
Aged, 80 and over
Antibodies, Neutralizing - blood
Antibodies, Neutralizing - immunology
Asymptomatic Diseases
COSIN
COVID
COVID-19 - immunology
COVID-19 - pathology
COVID-19 - virology
Female
functional MBCs
Humans
Limit of Detection
longitudinal tracking
Male
memory B cells
Memory B Cells - metabolism
Middle Aged
Neutralization Tests
neutralizing antibodies
Protein Domains - immunology
RBD
RBD tetramer
SARS-CoV-2
SARS-CoV-2 - isolation & purification
SARS-CoV-2 - metabolism
SARS-CoV-2 pseudovirus
Severity of Illness Index
Spike Glycoprotein, Coronavirus - chemistry
Spike Glycoprotein, Coronavirus - immunology
Spike Glycoprotein, Coronavirus - metabolism
Time Factors
Young Adult
title Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T06%3A31%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20persistence%20of%20RBD+%20memory%20B%20cells%20encoding%20neutralizing%20antibodies%20in%20SARS-CoV-2%20infection&rft.jtitle=Cell%20reports.%20Medicine&rft.au=Abayasingam,%20Arunasingam&rft.aucorp=on%20Behalf%20of%20the%20COSIN%20Study%20Group&rft.date=2021-04-20&rft.volume=2&rft.issue=4&rft.spage=100228&rft.epage=100228&rft.pages=100228-100228&rft.artnum=100228&rft.issn=2666-3791&rft.eissn=2666-3791&rft_id=info:doi/10.1016/j.xcrm.2021.100228&rft_dat=%3Cproquest_doaj_%3E2503669947%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c587t-c19ea1bd65128a1b1c01670ec2f669f8aec479d46ba11b5669c172dae934120e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2503669947&rft_id=info:pmid/33748788&rfr_iscdi=true